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Almost two decades after the first synthesis of the dideoxy apiose nucleosides, we sought to revisit their 
synthesis and convert them to the corresponding phosphoramidate (ProTides).  
 
INTRODUCTION 
 
Dideoxyapiose nucleosides (ddAN) were 
synthesized in the early 90’s as potential 
antivirals. However, the interest in this class of 
nucleosides faded away after they were reported 
to be inactive.
1 
It might be expected that the 
inadequate cellular conversion to the 
corresponding triphosphate is responsible for 
their non-activity. Recently, Herdewijn and 
coworkers showed that the related L-2-
deoxythreose nucleoside phosphonates (I; 
Figure 1) selectively inhibit HIV
 
without affecting human DNA synthesis.
2
 A serious 
problem associated with phosphonates, however, is their low bioavailability. Inspired by 
the cellular activity of I, we decided to reinvestigate the synthesis of the ddANs. Note 
that the monophosphate forms of the envisaged L-ddANs (II), can be considered as the 
parent nucleotides from which the bioisosteric phosphonates I have been derived. Since 
cellular conversion to this monophosphate might form the bottleneck in the activation of 
the ddANs, we decided to convert them in to their masked monophosphates (ProTides).
3
 
 
RESULTS AND DISCUSSION 
 
The threose compound 1 (Scheme 1) was synthesized following the reported procedure.
4
 
The oxidation of secondary hydroxyl group was performed using pyridinium 
chlorochromate (PCC). To avoid the toxicity issues pertaining to PCC, we explored 
alternative oxidation conditions. Surprisingly, TMPO-BAIB oxidation, text book 
conditions to convert primary alcohol groups to the corresponding acid without affecting 
other hydroxyl groups, proved a valuable alternative for oxidation of 1 to 2.  Initially, the 
key intermediate 7 was produced via compound 5,
5
 obtained by hydroxylation of 
exomethylene group of 3, but afterword we followed a shorter and more consistent route 
through the apiose derivative 5.  
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Ia  B = thymin-1-yl
            (PMDTT)
Ib  B = adenin-9-yl
            (PMDTA)
IIa  B = thymin-1-yl
IIb  B = adenin-9-yl
      FIGURE 1 
 The nucleobases were installed by modified Vorbrüggen coupling of 7 with the 
appropriate silylated bases, followed by removal of the acetyl and benzoyl groups 
(Scheme 2). The compounds 10 and 11 were obtained by Barton-McCombie 
deoxygenation. The ddAN 12 was obtained after palladium catalysed debzylation.  
The synthesis of the nucleoside analogue 13 and the final ProTides is in progress. The 
ability of these phosphoramidates to inhibit various viral strains will be discussed. 
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